Hematologic Malignancies

Researchers propose new risk groups for NK-AML

May 8, 2019

CAR T-cell therapy bb2121 performs well in phase 1 trial of refractory multiple myeloma

May 1, 2019

Advances in CAR T-Cell Therapies (FULL)

February 11, 2019

Obinutuzumab-based regimens yield durable remissions in CLL

January 16, 2019

10 Important VA Studies You Might Have Missed at ASH

December 14, 2018

2018: A banner year for hematology drug approvals

December 5, 2018

CLL resistance mechanism to venetoclax identified

December 5, 2018

Hematologic Malignancies

FDA approves rituximab biosimilar for lymphoma

November 28, 2018

Hematologic Malignancies

FDA expands approval of brentuximab vedotin to PTCL

November 16, 2018

Hematologic Malignancies

Bortezomib may unlock resistance in WM with mutations

November 15, 2018

Hematologic Malignancies

Azacitidine-nivolumab combo 'encouraging' in AML

November 14, 2018

P-BCMA-101 gains FDA regenerative medicine designation

November 9, 2018

What’s the Impact of Osteoporosis in Multiple Myeloma?

November 8, 2018

Variant not linked to CLL in Southeast Europe

November 7, 2018

Hematologic Malignancies

Researchers consider R/R ALL drugs in the first-line setting

October 17, 2018